BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
Investor Relations
Stock price graph

We are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). Our second proprietary drug candidate, BIND-510, is a prostate-specific membrane antigen (PSMA)-targeted Accurin nanoparticle containing vincristine and is currently in preclinical development. The Company has collaborated or is collaborating with Pfizer, AstraZeneca, Roche, Merck, and Amgen to develop Accurins based on therapeutic payloads from their product pipelines.

View all »   RSSRecent Releases

Mar 18, 2015
Data from Three Abstracts Validating Potential of BIND Therapeutics' Accurins™ to be Presented at American Association for Cancer Research Annual Meeting

Mar 11, 2015
BIND Therapeutics Reports Fourth Quarter and Full Year 2014 Financial Results


NASDAQ: BIND
Price:
5.49
Change:
+ 0.05
Day High:
5.55
Day Low:
5.37
Volume:
110,700
4:00 PM ET on Mar 31, 2015
Delayed at least 20 minutes.
Provided by eSignal.
Media Inquiries
Direct media inquiries to:
Gina Nugent
The Yates Network
gina@theyatesnetwork.com

Investor Inquiries
Direct investor inquiries to:
Beth DelGiacco
Stern Investor Relations, Inc.
212-362-1200
BIND@sternir.com